Clopidogrel as prophylactic treatment for migraine

• Research type

  Research Study

• Full title

  Clopidogrel as prophylactic treatment for migraine

• Contact name

  John Chambers

• Sponsor organisation

  (GSTFT) Guy's and St Thomas NHS Foundation Trust

• Eudract number

  2008-001604-23

• Research summary

  This is a double-blind placebo-controlled trial of Clopidogrel as prophylactic treatment for migraine involving 286 patients aged > 18 with more than 4 migraine attacks each month. Exclusions will be for high risk features suggesting cerebral malignancy, contraindications to clopidogrel therapy (hypersensitivity, active bleeding, warfarin therapy) or active need for clopidogrel (recent acute coronary syndrome, TIA with aspirin hypersensitivity). There will be a run-in period of one month on usual medication to determine the baseline frequency, severity and duration of headache followed by randomisation to placebo or clopidogrel 75 mg once daily for 3 months. At the end of the study the patient will be free to take open-label clopidogrel. Subjects will undergo a standard transthoracic study with up to 4 injections of agitated saline immediately after release of a valsalva manoeuvre13.

• REC name

  London - London Bridge Research Ethics Committee

• REC reference

  07/H0804/139

• Date of REC Opinion

  3 Dec 2008

• REC opinion

  Further Information Favourable Opinion